Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-673-3 | CAS number: 124-04-9
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
Additional information
The OECD/ICCA high production volume chemicals program discussed data on adipic acid during SIAM 18, April 2004. This evaluation is published by UNEP. Overall it is concluded in the SIDS Initial Assessment Profile that: “The chemical is currently of low priority for further work.”
The rational for this recommendation was as follows: “The chemical possesses properties (eye and respiratory tract irritation) indicating a hazard for human health. Although these hazards do not warrant further work, they should nevertheless be noted by chemical safety professionals and users, especially at the workplace.”
The IUCLID dataset and the present Human Health Hazard Assessment is based on the recent OECD/ICCA evaluation. For all endpoints the hazards identified and discussed in the OECD SIDS Initial Assessment Report for adipic acid in 2004 are cited and additional updated relevant information is given in a separate heading.
Non-human information:
Hazards identified by OECD/ICCA high production volume chemicals program in 2004:
"After oral administration by gavage of radioactive adipic acid to fasted rats up to 70 % of the dose was exhaled as CO2. In the urine the parent compound adipic acid and metabolic products identified as urea, glutamic acid, lactic acid, beta-ketoadipic acid and citric acid were found (percentages not specified). Adipic acid was metabolized by beta-oxidation in a similar fashion as fatty acids and acetate was a metabolite of adipic acid. Radioactive glycogen was isolated in experiments where glycogen formation in the liver was encouraged by oral administration of glucose together with radioactive adipic acid (Rusoff et al. 1960). When adipic acid or its sodium salt was administered to non fasted rats, rabbits and one dog 18 – 71 % of the doses were excreted in the urine. Breath was not analyzed in these studies (Mori 1918; Bernhard and Andreae 1937; Enders 1941). In an oral 28-day subacute study in rats excretion of adipic acid was similar from day 1 to 28, indicating that adipic acid did not accumulate during the treatment. Breath was not analyzed, (Enders 1941). It is unclear whether the methods of detection in these early studies were reliable."
Updated relevant information:
None
Human information
Hazards identified by OECD/ICCA high production volume chemicals program in 2004:
"Adipic acid was orally administered to humans to investigate compound excretion. The highest dose administered in one volunteer was 70 g over 10 days. 3 other persons took 19 to 23.4 g over up to 9 days. 15 - 75 % of the adipic acid dose was found unchanged in the urine after oral administration of up to 7 g of adipic acid over up to 10 days to 7 volunteers. Breath was not analyzed, and it is unclear whether the methods of detection used were reliable (Weitzel 1942 and 1947)."
Updated relevant information:
None
Conclusion:
In limited studies in animals and humans it was shown that adipic acid is absorbed after oral administration, partially metabolized to various metabolites and CO2 which are excreted via urine and breath, resp.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
